CO2022001482A2 - Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida - Google Patents

Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Info

Publication number
CO2022001482A2
CO2022001482A2 CONC2022/0001482A CO2022001482A CO2022001482A2 CO 2022001482 A2 CO2022001482 A2 CO 2022001482A2 CO 2022001482 A CO2022001482 A CO 2022001482A CO 2022001482 A2 CO2022001482 A2 CO 2022001482A2
Authority
CO
Colombia
Prior art keywords
methyl
methoxyazetidin
dihydropyridin
dioxole
methylthio
Prior art date
Application number
CONC2022/0001482A
Other languages
English (en)
Inventor
Victor S Gehling
Alamelu Banda
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of CO2022001482A2 publication Critical patent/CO2022001482A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se refiere a una Forma cristalina 1 de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida, que es útil como modulador de la actividad de las enzimas modificadoras de metilo de las histonas. La presente descripción también proporciona composiciones farmacéuticamente aceptables que comprenden la forma cristalina y métodos para usar dichas composiciones en el tratamiento de diversos trastornos.
CONC2022/0001482A 2019-07-24 2022-02-15 Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida CO2022001482A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878012P 2019-07-24 2019-07-24
PCT/US2020/043178 WO2021016414A1 (en) 2019-07-24 2020-07-23 Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Publications (1)

Publication Number Publication Date
CO2022001482A2 true CO2022001482A2 (es) 2022-03-18

Family

ID=72047059

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001482A CO2022001482A2 (es) 2019-07-24 2022-02-15 Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Country Status (14)

Country Link
US (1) US20220251073A1 (es)
EP (1) EP4003532A1 (es)
JP (1) JP2022541630A (es)
KR (1) KR20220041129A (es)
CN (1) CN114450279A (es)
AU (1) AU2020316073A1 (es)
BR (1) BR112022001161A2 (es)
CA (1) CA3148447A1 (es)
CL (1) CL2022000175A1 (es)
CO (1) CO2022001482A2 (es)
IL (1) IL289972A (es)
MX (1) MX2022000931A (es)
PE (1) PE20220562A1 (es)
WO (1) WO2021016414A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20230110210A (ko) * 2022-01-14 2023-07-21 동화약품주식회사 1,3-벤조다이옥솔 유도체 화합물 및 이를 포함하는 약학적 조성물
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2024015566A1 (en) 2022-07-15 2024-01-18 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of at-rich interactive domain-containing protein 1a (arid1a) mutated cancers
CN115403040B (zh) * 2022-08-11 2023-08-01 中国地质大学（北京） 一种可通过光辐射调控导热系数的偶氮苯聚合物表面修饰的金刚石纳米粒子及其制备方法
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024076663A1 (en) 2022-10-06 2024-04-11 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of brca1-associated protein (bap1) mutated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128556A1 (en) * 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MA38341B1 (fr) * 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
DK3121175T3 (da) * 2014-03-17 2020-03-09 Daiichi Sankyo Co Ltd 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
US10577350B2 (en) * 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
KR20190105602A (ko) * 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
UA127357C2 (uk) * 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання

Also Published As

Publication number Publication date
BR112022001161A2 (pt) 2022-06-07
KR20220041129A (ko) 2022-03-31
MX2022000931A (es) 2022-05-03
EP4003532A1 (en) 2022-06-01
JP2022541630A (ja) 2022-09-26
IL289972A (en) 2022-03-01
AU2020316073A1 (en) 2022-02-17
US20220251073A1 (en) 2022-08-11
PE20220562A1 (es) 2022-04-13
WO2021016414A1 (en) 2021-01-28
CA3148447A1 (en) 2021-01-28
CL2022000175A1 (es) 2022-09-20
CN114450279A (zh) 2022-05-06

Similar Documents

Publication Publication Date Title
CO2022001482A2 (es) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
CL2019002664A1 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados.
CO2018003168A2 (es) Moduladores de la expresión de kras
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
AR098693A1 (es) Método para producir células del epitelio pigmentario retiniano (rpe)
CO7240408A2 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
AR090970A1 (es) Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
CR9723A (es) Nueva forma cristalina de un derivado de piridazino[4,5-b] indol
AR086281A1 (es) Composiciones y metodos que comprenden variantes de serina proteasas
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
ECSP20068210A (es) Moduladores calpaína y usos terapéuticos de los mismos
PE20160519A1 (es) Compuestos de tetrahidrocarbozol y carbozol carboxamida sustituidos utiles como inhibidores de cinasa
CO2017004517A2 (es) Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration
NI201600149A (es) Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasa
CL2021002963A1 (es) Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer
CL2022002985A1 (es) Inhibidores de pi3k y métodos de uso de los mismos
UY34976A (es) Formas sólidas de un compuesto antiviral
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
PE20151142A1 (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
CO2022017233A2 (es) 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis